Trial Profile
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2020
Price :
$35
*
At a glance
- Drugs Ipafricept (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 12 Jul 2020 Status changed to discontinued, according to results published in the Clinical Cancer Research
- 12 Jul 2020 Results published in the Clinical Cancer Research
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium